FDA approves new silicone breast implant from Allergan

Wed Feb 20, 2013 6:15pm EST

Related Topics

(Reuters) - Health regulators said on Wednesday they have approved a new silicone gel-filled breast implant made by Allergan Inc.

The U.S. Food and Drug Administration said it approved Allergan's Natrelle 410 implants to increase breast size in women 22 years and older and to rebuild breast tissue in women of any age.

The silicone gel in the Natrelle 410 implant is designed to be firmer than that in Allergan's previous Natrelle implant.

The FDA requires Allergan to conduct a series of studies after the product is approved to assess the long term safety. It must follow about 3,500 women for five years and conduct a 10-year study of more than 2,000 women receiving the implant.

The agency based its approval on seven years of data from 941 women. Most complications were similar to those found in previous breast implant studies, including tightening of the area around the implant, re-operation, implant removal and infection.

(Reporting By Toni Clarke; Editing by Tim Dobbyn)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
JackTraveler wrote:
If the complications were similar to those of previous implants, “similar to those found in previous breast implant studies, including tightening of the area around the implant, re-operation, implant removal and infection,” which were removed from the market, then why were these approved? The FDA needs to educate us about this approval process. It doesn’t make any sense to me

Feb 20, 2013 11:09pm EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.